Cellular pharmacology of anthracycline resistance and its circumvention

H. Tapiero, A. Fourcade, J. N. Munck, G. Zwingelstein, T. J. Lampidis

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

Adriamycin-resistant cells express a multiple drug resistance phenotype characterized by cross-resistance to compounds of related and unrelated structure and action. The pharmacological determinants of this resistance, such as decreased drug uptake and/or decreased drug retention, are associated with biochemical alterations in the cells. To overcome multiple drug resistance, a calcium-channel blocking agent, verapamil, was used, which acted by increasing the amount of drug retained in resistant cells and consequently enhanced the cytotoxic effectiveness. The basis for this enhanced retention and cytotoxicity is not known. Whether these compounds sensitize the cells to the action of, or potentiate the effect of, anticancer drugs remains to be determined. The preliminary data tend to support the second possibility.

Original languageEnglish (US)
Pages (from-to)265-273
Number of pages9
JournalDrugs under Experimental and Clinical Research
Volume12
Issue number1-3
StatePublished - May 14 1986
Externally publishedYes

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Cellular pharmacology of anthracycline resistance and its circumvention'. Together they form a unique fingerprint.

  • Cite this